RNA Tech Vax Developer GreenLight Biosciences Rides To NASDAQ Debut Via $1.5B SPAC Deal

 

• GreenLight Biosciences Inc is combining with a special-purpose acquisition company to go public in a deal that values the RNA-technology firm at about $1.5 billion.
• GreenLight is merging with Environmental Impact Acquisition Corp ENVI 1.03%, which is backed by investment bank Canaccord Genuity Group Inc.
• GreenLight's ribonucleic acid (RNA) platform has developed candidates for COVID-19, influenza, and earlier-stage programs in sickle cell disease. It is simultaneously working on RNA-based sustainable alternatives to pesticides and herbicides. 
• The first biopesticide is slated to launch in 2022, the company said at the time of its series D.
• The transaction will provide estimated proceeds of $282 million, including $105 million in proceeds from the PIPE transaction priced at $10.00 per share.

https://www.benzinga.com/general/biotech/21/08/22427899/rna-tech-vaccine-developer-greenlight-biosciences-riding-to-nasdaq-debut-via-1-5b-spac-deal